Kirujan Jeyakumar, M.Sc.

Position: PhD Student

Room no.: CP-02-110

Telephone no.: +49 231 755 7053

Member of the group since: 11/2017

University degree: M. Sc. in Chemical Biology, TU Dortmund University


Expertise: organic synthesis, parallel synthesis, small scale synthesis, multiparameter optimization, biochemical assays, stem cell culture, stem cell differentiation, cellular assays

Off-Lab activities (hobbies): music, sports, cooking, games, reading, spending time with Friends

Research projects:

As an alternative to chemotherapy in the context of non-small cell lung cancer, small molecule treatment is an effective strategy. This medicinal chemistry project aims at targeting mutants of the ErbB receptor tyrosine kinase family (EGFR, HER2). Techniques and strategies compromise structure-based drug design, organic synthesis and evaluation of synthesized compounds in biochemical and cellular assays.


Earlier Positions:

  • Bachelor Studies at the TU Dortmund in the group of Prof. Dr. Dennis Schade on cultivation, characterization and differentiation of hIPSC and mESC
  • Master studies at the Max-Planck-Institute of Molecular Physiology in the group of Dr. Andrey Antonchick on metal-free C–H bond functionalization, metal-free C-O activation, multicomponent reactions, DNA-encoded libraries and metal-free radical azidoarylation



1. Bering, L.; Jeyakumar, K.; Antonchick, A. P.: Metal-Free C-O Bond Functionalization: Catalytic Intramolecular and Intermolecular Benzylation of Arenes. Org. Lett. 2018, 20 (13), 3911–3914.

DOI PubMed

2. Lategahn, J.; Hardick, J.; Grabe, T.; Niggenaber, J.; Jeyakumar, K.; Keul, M.; Tumbrink, H. L.; Becker, C.; Hodson, L.; Kirschner, T.; Klövekorn, P.; Ketzer, J.; Baumann, M.; Terheyden, S.; Unger, A.; Weisner, J.; Müller, M. P.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.: Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J. Med. Chem. 2020, 63 (20), 11725–11755.

DOI PubMed

3. J. Lategahn, H. L. Tumbrink, C. Schultz-Fademrecht, A. Heimsoeth, L. Werr, J. Niggenaber, M. Keul, F. Parmaksiz, M. Baumann, S. Menninger, E. Zent, I. Landel, J. Weisner, K. Jeyakumar, L. Heyden, N. Russ, F. Müller, C. Lorenz, J. Brägelmann, I. Spille, T. Grabe, M. P. Müller, J. M. Heuckmann, B. Klebl, P. Nussbaumer, M. L. Sos, and D. Rauh.: Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. J. Med. Chem. 2022, 65 (9), 6643-6655.

DOI PubMed

4. H. Chauvistré, B. Shannan, S. M. Daignault-Mill, R. J. Ju, D. Picard, S. Egetemaier, R. Váraljai, C. S. Gibhardt, A. Sechi, F. Kaschani, O. Keminer, S. J. Stehbens, Q. Liu, X. Yin, K. Jeyakumar, F. C. E. Vogel, C. Krepler, V. W. Rebecca, L. Kubat, S. S. Lueong , J. Forster, S. Horn, M. Remke, M. Ehrmann, A. Paschen, J. C. Becker , I. Helfrich , D. Rauh, M. Kaiser, S. Gul, M. Herlyn, I. Bogeski, J. N. Rodríguez-López, N. K. Haass, D. Schadendorf, A. Roesch.: Persister state-directed transitioning and vulnerability in melanoma. Nat. Commun. 2022, 13, 3055.

DOI PubMed

5. T. Grabe, K. Jeyakumar, J. Niggenaber, T. Schulz, S. Koska, S. Kleinbölting, M. E. Beck, M. P. Müller, and D. Rauh.: Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines. ACS Med. Chem. Lett. 2023, 14 (5), 591-598.

DOI PubMed